220 related articles for article (PubMed ID: 28641031)
41. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
42. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
43. Improving the economics of NASH/NAFLD treatment through the use of systems biology.
Bosley J; Boren C; Lee S; Grøtli M; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Drug Discov Today; 2017 Oct; 22(10):1532-1538. PubMed ID: 28736156
[TBL] [Abstract][Full Text] [Related]
44. Nonalcoholic fatty liver disease - current status and future directions.
Demir M; Lang S; Steffen HM
J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
[TBL] [Abstract][Full Text] [Related]
45. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
[TBL] [Abstract][Full Text] [Related]
46. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
Delarue J; Lallès JP
Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
[TBL] [Abstract][Full Text] [Related]
48. Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
[TBL] [Abstract][Full Text] [Related]
49. Investigational drugs in systemic vasculitis.
Mirouse A; Cacoub P; Desbois AC; Comarmond C; Pagnoux C; Saadoun D
Expert Opin Investig Drugs; 2017 Sep; 26(9):1049-1061. PubMed ID: 28758504
[TBL] [Abstract][Full Text] [Related]
50. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.
Rau M; Geier A
Expert Rev Clin Pharmacol; 2021 Mar; 14(3):333-340. PubMed ID: 33535836
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
52. Leptin in nonalcoholic fatty liver disease: a narrative review.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2015 Jan; 64(1):60-78. PubMed ID: 25456097
[TBL] [Abstract][Full Text] [Related]
53. The molecular basis for current targets of NASH therapies.
Qureshi K; Neuschwander-Tetri BA
Expert Opin Investig Drugs; 2020 Feb; 29(2):151-161. PubMed ID: 31847612
[No Abstract] [Full Text] [Related]
54. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
Huber Y; Galle PR; Schattenberg JM
Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
[TBL] [Abstract][Full Text] [Related]
55. Emerging therapeutic targets for NASH: key innovations at the preclinical level.
Horn P; Newsome PN
Expert Opin Ther Targets; 2020 Mar; 24(3):175-186. PubMed ID: 32053033
[No Abstract] [Full Text] [Related]
56. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
57. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement.
Nobili V; Vajro P; Dezsofi A; Fischler B; Hadzic N; Jahnel J; Lamireau T; McKiernan P; McLin V; Socha P; Tizzard S; Baumann U
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):550-61. PubMed ID: 25591123
[TBL] [Abstract][Full Text] [Related]
58. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
59. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
Musso G; Gambino R; Cassader M; Pagano G
Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
[TBL] [Abstract][Full Text] [Related]
60. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.
Do A; Ilagan-Ying YC; Mehal WZ; Lim JK
Expert Opin Drug Discov; 2021 Feb; 16(2):125-134. PubMed ID: 33086894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
